< Back to the team

H.GISSEROT

Board member

Hervé Gisserot is an experienced business leader with a strong track record in the pharmaceutical industry.

He is currently the General Manager of CSL Vifor and was previously the President of LEEM (French Pharma Association) and CEO of GSK France.

He has a wealth of knowledge and experience in the field, and is committed to driving innovation and growth in the industry.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page